Tag: EAU15

EAU15: Cracking the biomarker market

The current biomarker research field is humming with activity but the numbers and frequency of new biomarkers coming in doesn’t always translate to efficient clinical use, prompting researchers to ask if their efforts are worth the long and tedious...

EAU15: mCRPC looks at novel research

Much research has been done on new treatment modalities for patients with metastatic castration-resistant prostate cancer (mCRPC) but the cross resistance between these therapies needs to be understood better. Another relative new topic of research is the quality of...

EAU15: Measuring and improving prostate cancer care

Medical coverage in the United States presents unique challenges related to costs. They can be tackled through enabling partnerships between the medical community and insurance companies, but most importantly, by thinking out of the box. One example of collaboration...

EAU15: Trends in bladder cancer treatment

Bladder cancer is a common urological malignancy but is much more complex compared to others because of multiple mutations in cells. Moreover, treatment is expensive because of the high risk of recurrence and the cost of cystoscopies. During Thematic...

EAU15: High risk PCa: Better curative therapy remains elusive

Experts examined yesterday controversies, treatment insights and uncertainties in multi-modal approaches in prostate cancer during Plenary Session 2 with some speakers underscoring the lack of convincing data and others reiterating the message that, at best, patients with aggressiveprostate cancer...

Chapple assumes Secretary General post

Barely two hours after the second day of the Congress opened with the EAU General Assembly, the association welcomed a new Secretary General and a new Executive Member responsible for Science. Professors Chris Chapple (GB) and Francesco Montorsi (IT)...

Are there useable molecular markers for prostate cancer?

There is no doubt that we need more and better markers to determine risk, presence, aggressiveness and therapy response of prostate cancer (PCa). Besides physical symptoms such as palpable irregularities upon digital rectal examination (DRE), current indicators range from...

Surgery or radiotherapy: Treatment decision for high-risk PCa

Due to the absence of randomized data clearly showing a superiority of one treatment option over the others in terms of classical survival endpoints, patients diagnosed with High-Risk Prostate Cancer (HRPCa) are currently basing their choice mostly on individual...

EAU15: Future of targeted prostate cancer treatment

As treatment options become more refined and comprehensive, the tools available to the urologist or clinical oncologist to effectively target this treatment become more important. Systems that give precision on a molecular level are becoming a reality. A substantial...